The approval relies on positive data from the POTOMAC Phase III trial.

older person in a hospital bed talking to a doctor-1 Original Medicare (parts A and B) covers approved treatments and services for bladder cancer that your healthcare team deems medically necessary, ...

ImmunityBio Inc. IBRX on Monday said it entered an exclusive U.S. Development and Supply Agreement with Japan BCG Laboratory to develop, import, and commercialize the Tokyo strain of BCG for bladder ...

ImmunityBio Inc. (NASDAQ:IBRX) is one of the most shorted mid-cap and small-cap stocks to buy now. On May 19, Immunitybio Inc ...

Amid a global drug shortage, thousands of patients with bladder cancer are unable to receive their recommended treatment each year. While Merck has pledged to make as many doses as it can, the company ...

Use of 2 sequential induction courses of BCG for high-risk NMIBC rather than standard induction with maintenance therapy showed an excellent response rate. A novel strategy for using bacillus Calmette ...

Anktiva boosted responses to BCG treatment without affecting quality of life, research showed. A novel “immune enhancer” improved outcomes and did not affect quality of life in patients with Bacillus ...

Anktiva plus BCG aims to treat BCG-unresponsive NMIBC with papillary disease, potentially reducing radical cystectomy need. The treatment showed high rates of surgery avoidance and disease-free ...